Elafibranor has 'significant, sustained treatment benefit' in PBC through 78 weeks

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.“There is a major unmet need for a primary biliary cholangitis (PBC) treatment that effectively targets the biochemical indicators of disease

Related Keywords

Boston , Massachusetts , United States , Zurich , Züsz , Switzerland , Milan , Lombardia , Italy , Christelle Huguet , Bymonica Stonehill , Andrease Kremer , Heather Biele , Christopherl Bowlus , University Hospital Zurich , Uc Davis Health , Liver Meeting ,